Forte Biosciences Inc.

1.30+0.0700+5.69%Vol 1.66M1Y Perf -96.63%
Jun 24th, 2022 16:00 DELAYED
BID1.30 ASK1.33
Open1.22 Previous Close1.23
Pre-Market- After-Market1.30
 - -  - -%
Target Price
3.50 
Analyst Rating
Moderate Buy 2.33
Potential %
169.23 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
0.73 
Earnings Rating
Market Cap19.19M 
Earnings Date
15th Aug 2022
Alpha0.16 Standard Deviation1.47
Beta1.60 

Today's Price Range

1.191.33

52W Range

1.0337.85

Summary:

Buy

Technical Indicators: Strong Buy
Moving Averages: Buy
Performance
1 Week
12.07%
1 Month
6.56%
3 Months
-14.47%
6 Months
-41.44%
1 Year
-96.63%
3 Years
-98.63%
5 Years
-99.38%
10 Years
-

TickerPriceChg.Chg.%
FBRX1.300.07005.69
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022--0.17-
Q03 2021-0.29-0.54-86.21
Q02 2021-0.40-0.43-7.50
Q01 2021-0.39-0.367.69
Q03 2020-0.32-0.46-43.75
Q02 2020--9.52-
Q01 2020--6.45-
Q04 2019-8.25-6.6020.00
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date15th Aug 2022
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1.66M
Shares Outstanding14.76K
Shares Float11.25M
Trades Count2.53K
Dollar Volume2.15M
Avg. Volume177.88K
Avg. Weekly Volume218.31K
Avg. Monthly Volume153.87K
Avg. Quarterly Volume161.45K

Forte Biosciences Inc. (NASDAQ: FBRX) stock closed at 1.3 per share at the end of the most recent trading day (a 5.69% change compared to the prior day closing price) with a volume of 1.66M shares and market capitalization of 19.19M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 9 people. Forte Biosciences Inc. CEO is Paul A. Wagner.

The one-year performance of Forte Biosciences Inc. stock is -96.63%, while year-to-date (YTD) performance is -39.25%. FBRX stock has a five-year performance of -99.38%. Its 52-week range is between 1.03 and 37.85, which gives FBRX stock a 52-week price range ratio of 0.73%

Forte Biosciences Inc. currently has a PE ratio of -0.90, a price-to-book (PB) ratio of 0.43, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.91%, a ROC of -41.10% and a ROE of -42.47%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Forte Biosciences Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Forte Biosciences Inc.’s next earnings report date is 15th Aug 2022.

The consensus rating of Wall Street analysts for Forte Biosciences Inc. is Moderate Buy (2.33), with a target price of $3.5, which is +169.23% compared to the current price. The earnings rating for Forte Biosciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Forte Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Forte Biosciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 36.46, ATR14 : 0.09, CCI20 : 74.40, Chaikin Money Flow : 0.18, MACD : 0.00, Money Flow Index : 65.33, ROC : 0.00, RSI : 56.06, STOCH (14,3) : 69.57, STOCH RSI : 1.00, UO : 56.03, Williams %R : -30.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Forte Biosciences Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (33.33 %)
2 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (66.67 %)
2 (66.67 %)
2 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.33
Moderate Buy
2.33
Moderate Buy
2.00

Forte Biosciences Inc.

Forte Biosciences Inc is a clinical-stage biopharmaceutical company, focused on dermatology. The company is developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric patients with atopic dermatitis. It plans to advance FB-401 into a randomized Phase 2 clinical trial.

CEO: Paul A. Wagner

Telephone: +1 310 618-6994

Address: 1124 W Carson Street, Torrance 90502, CA, US

Number of employees: 9

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

News

Stocktwits